These findings demonstrate that high-level expression of PRDX4 and GSN might contribute to CRC progression (p = 0.04 and p = 0.02; Table 3) and may be a potential target for the treatment of this disease. This evidence concerns the gene PRDX4 and colorectal carcinoma.